A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: Daratumumab
DRUG: Cyclophosphamide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Janssen Research & Development, LLC